Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: Prospective multicenter study

American Journal of Gastroenterology

Volumn 103, Issue 6, 2008, Pages 1496-1504

  Shastri, Yogesh M ^a   Loitsch, Stefan ^a   Hoepffner, Nicolas ^a,b   Povse, Nada ^a   Hanisch, Ernst ^c   Rösch, Wolfgang ^d   Mössner, Joachim ^e   Stein, Jürgen M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Bethanien Krankenhaus Frankfurt   (Germany)

^c Asklepios Hospital   (Germany)

^d Nordwest Hospital   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN; PYRUVATE KINASE; PYRUVATE KINASE M2;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHROMATOGRAPHY; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; OFFICE VISITS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRUVATE KINASE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 44949245721     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01824.x     Document Type: Article

References (49)

1. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 2006 56 : 11 25 quiz 49-50.
2. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology 2004 127 : 1661 9.
3. Levin TR. Colonoscopy capacity: Can we build it? Will they come? Gastroenterology 2004 127 : 1841 4.
4. Kowalczyk L. Colonoscopies tax health industry. Boston Globe, August 1, 2004, section 1.
5. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993 328 : 1365 71.
6. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996 348 : 1472 7.
7. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996 348 : 1467 71.
8. Fludger S, Turner AM, Harvey RF, et al. Controlled prospective study of faecal occult blood screening for colorectal cancer in Bury, black pudding capital of the world. BMJ 2002 325 : 1444 5.
9. Fraser CG, Matthew CM, Mowat NA, et al. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: An observational study. Lancet Oncol 2006 7 : 127 31.
10. Ward N, Wright J, Marsh S, et al. Fast track referrals for colorectal cancer: The impact of the faecal occult blood test screening programme. Colorectal Dis 2007 9 : 258 61.
11. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996 334 : 155 9.
12. Zappa M, Castiglione G, Paci E, et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: The District of Florence experience. Int J Cancer 2001 92 : 151 4.
13. Hisamichi S, Fukao A, Fujii Y, et al. Mass screening for colorectal cancer in Japan. Cancer Detect Prev 1991 15 : 351 6.
14. Imperiale TF. Quantitative immunochemical fecal occult blood tests: Is it time to go back to the future? Ann Intern Med 2007 146 : 309 11.
15. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005 129 : 422 8.
16. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007 146 : 244 55.
17. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005 100 : 2519 25.
18. Hoepffner N, Shastri YM, Hanisch E, et al. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther 2006 23 : 145 54.
19. Trojan J, Povse N, Schroder O, et al. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. Z Gastroenterol 2002 40 : 921 4.
20. Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000 20 : 4965 8.
21. Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: In a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004 91 : 980 4.
22. Shastri YM, Naumann M, Oremek GM, et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006 119 : 2651 6.
23. Haug U, Wente MN, Seiler CM, et al. Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: Stability at room temperature and implications for application in the screening setting. Clin Chem 2006 52 : 782 4.
24. Eigenbrodt E, Fister P, Reinacher M. New perspectives on carbohydrate metabolism in tumor cells. In Beitner, ed. Regulation of carbohydrate metabolism, volume II. Boca Raton, FL : CRC Press, 1985 : 141 79.
25. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005 15 : 300 8.
26. Kumar Y, Tapuria N, Kirmani N, et al. Tumour M2-pyruvate kinase: A gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 2007 19 : 265 76.
27. Walkowiak J, Banasiewicz T, Krokowicz P, et al. Fecal pyruvate kinase (M2-PK): A new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol 2005 40 : 1493 4.
28. Deeks JJ, Altman DG. Diagnostic tests 4: Likelihood ratios. BMJ 2004 329 : 168 9.
29. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993 39 : 561 77.
30. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol 2005 23 : 293 300.
31. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998 338 : 1089 96.
32. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006 12 : 7007 11.
33. Shastri YM, Stein JM. Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening. World J Gastroenterol 2007 13 : 2768 9.
34. Crotta S, Castiglione G, Grazzini G, et al. Feasibility study of colorectal cancer screening by immunochemical faecal occult blood testing: Results in a northern Italian community. Eur J Gastroenterol Hepatol 2004 16 : 33 7.
35. Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005 115 : 493 6.
36. Fenocchi E, Martinez L, Tolve J, et al. Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev 2006 15 : 384 90.
37. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007 56 : 210 4.
38. Smith A, Young GP, Cole SR, et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006 107 : 2152 9.
39. Read TE, Read JD, Butterly LF. Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl J Med 1997 336 : 8 12.
40. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997 112 : 24 8.
41. Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of adenomas missed by optical colonoscopy. Ann Intern Med 2004 141 : 352 9.
42. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000 342 : 1149 55.
43. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000 342 : 1156 62.
44. Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J Math Psychol 1975 12 : 387 415.
45. Koopman PAR. Confidence intervals for the ratio of two binomial proportions. Biometrics 1984 40 : 513 7.
46. Hardt PD, Toepler M, Ngoumou B, et al. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003 23 : 851 3.
47. Naumann M, Schaum B, Oremek GM, et al. Faecal pyruvate kinase type M2 - a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004 129 : 1806 7.
48. Vogel T, Driemel C, Hauser A, et al. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005 130 : 872 7.
49. Haug U, Rothenbacher D, Wente MN, et al. Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults versus colorectal cancer patients. Br J Cancer 2007 96 : 1329 34.